A Phase Iii, Multicenter, Randomized Study Of Atezolizumab (Anti−Pdl1 Antibody) In Combination With Enzalutamide Versus Enzalutamide Alone In Patients With Metastatic Castrationresistant Prostate Cancer After Failure Of An Androgen Synthesis Inhibitor And Failure Of, Ineligibility For, Or Refusal Of A Taxane Regimen